Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in IDEXX Laboratories, Inc. $IDXX

Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 114,154 shares of the company’s stock after buying an additional 909 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.14% of IDEXX Laboratories worth $77,426,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of IDXX. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories in the third quarter valued at approximately $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter worth $30,000. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter worth $31,000. Finally, Salomon & Ludwin LLC purchased a new position in IDEXX Laboratories during the 3rd quarter worth $35,000. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IDXX shares. UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Barclays decreased their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Finally, Citigroup initiated coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $760.00.

IDEXX Laboratories Stock Performance

IDXX opened at $578.35 on Thursday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12-month low of $424.48 and a 12-month high of $769.98. The firm has a 50 day moving average of $597.21 and a two-hundred day moving average of $653.88. The firm has a market capitalization of $45.94 billion, a PE ratio of 44.25, a P/E/G ratio of 3.46 and a beta of 1.72.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.08 EPS for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the firm earned $2.53 EPS. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 14.54 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the sale, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 45,957 shares of company stock worth $29,862,109. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.